Clinical trials accepted for presentation will be:
Presented during the Late Breaking Clinical Trails session
Abstracts will be published in the August 2018 supplemental issue of the Journal of Cardiac Failure. Authors will have the ability to update the submitted abstract prior to publication. JCF encourages all accepted Late Breaking Clinical Trials to submit full papers for further consideration.
All late breaking data is embargoed until the day of the presentation. Please read Embargo Policy.
If late breaking clinical trial is accepted for a Late Breaking Trial Session and was submitted and accepted for abstract/poster presentation, it needs to be withdrawn from the abstract supplement by July 13, 2018.
HFSA is looking for imaginative, insightful and humorous submissions for the 2018 Hyde Park Session. Presentations should be clever and should challenge current opinion. The audience should laugh its way to new insights. Each presentation will be followed by 5 minutes of challenging and sometimes lively discussions. Submissions will be judged based on originality and potential interest for the audience. Up to six abstracts will be selected for presentation in the Hyde Park Session.
Speakers will have the opportunity to expound for 10 minutes on any topic related to heart failure. Hyde Park is a democratically structured session, unfettered by the usual standards of peer review.
Speakers may wish to:
Present a novel hypothesis, which may or may not be supported by real data.
Present a contrarian point of view, just for the fun of taking an unpopular position
Posit, complain, cajole or provoke, in an effort to force audience reactions that run the gamut from disbelief to reluctant acceptance.
Take a look at a previous Hyde Parks session for examples of what imaginative and humorous presentations you can expect!
Clinical Trial Row provides a designated research focus in the Exhibit Hall. It consists of poster boards providing information about:
Trial in the recruitment or follow-up phase.
How to get involved in company-supported research
Examples of information included on the poster board:
How to become a center
List of centers participating
Name of trial
Payments to centers
Source of financial support
How to become involved in company-based research
Boards may be staffed at any time during regular Exhibit Hall hours to answer questions. There will be required days and times that posters must be staffed. The schedule will be available in the exhibitor prospectus.
Location Information should be placed on 4×8 foot poster board in a dedicated area in the Exhibit Hall in the Gaylord Convention Center. Posters can include a pocket with informational brochures.
All Clinical Trial Row posters received by the deadline will be listed in the Annual Meeting final program book.
Clinical Trial Row will be included in an email to pre-registrants about Exhibit Hall activities.
Clinical Trial Row will be included in an announcement of Exhibit Hall activities included in conference attendee bags.
All Clinical Trial Row posters will be displayed on the HFSA website following the Annual Meeting.
All other rules for exhibiting apply. Payment must be received by July 31, 2018 to have submissions included in the HFSA Scientific Meeting program and posted on the exhibit hall floor. If you have questions, please contact Patrice Guzman at firstname.lastname@example.org or 301-312-8635. If interested, please complete this form and return it to email@example.com. You will be invoiced for payment. Submission Deadline: Friday, July 13, 2018.
Notification and acceptance emails will be sent to selected abstract authors
HFSA appreciates the significance that research plays in the future of patient care and in the development of young researchers. Posters and oral abstract presentations are an essential part of the HFSA Annual Scientific Meeting and submissions are encouraged from all professional disciplines.
HFSA’s 22nd Annual Scientific Meeting will once again feature posters, oral presentations, oral abstract award sessions, and a special supplemental Issue of the Journal of Cardiac Failure with published abstracts. The 2017 full supplement can be viewed here.
Accepted abstracts will be displayed as posters in a designated section of the Exhibit Hall from Saturday – Monday, September 15-17, 2018. Award Sessions and oral presentations are included in the scientific program.
Abstracts on heart failure research are invited in the following categories:
Biomarkers / Neurohormones / Cytokines
Cardiovascular Structure / Imaging
Electrophysiology / Arrhythmias
Epidemiology / Prevention
Management Strategies / Adherence / Self Care
Molecular Biology / Genetics / Cell Therapy
Performance Improvement Initiatives/Case Studies*
Quality of Care / Outcomes
Surgery / Transplantation / Devices
*Note: Case Studies and Performance Improvement Initiative abstracts are not eligible for awards.
Investigator Awards & Oral Presentations
HFSA offers three award competitions at its annual meeting:
Jay N. Cohn New Investigator Award – Basic Science
Jay N. Cohn New Investigator Award – Clinical/Integrative Physiology
Nursing Investigator Award
These awards are to recognize research excellence in young trainees and investigators. Finalists will present their work orally in scientific sessions.
Jay N. Cohn New Investigator Awards
A review committee will choose up to five finalists in each of two categories:
Clinical/integrative physiology research
Eligibility: Candidates must have completed training no earlier than 2014, be first author, and have played a major role in research study being submitted. The finalist must present their research results in respective JNC award sessions during the 22nd Annual Scientific Meeting.
Nursing Investigator Award
Nursing Investigator Award
This award recognizes outstanding and innovative research in the field of heart failure by a nurse researcher. Up to five finalists are chosen.
Eligibility: Candidate must be a nurse investigator or a student in an accredited nursing program and first author and presenter of the abstract submitted. Candidate cannot be a member of the HFSA Nursing Award Committee. Previous finalists for this award are ineligible. Individuals cannot apply for both the Clinical Excellence in Nursing and Nursing Research Awards in the same year.
Award finalists will be notified in early June. Monetary awards are provided to first and second place presenters. All award finalists receive complimentary registration.
Note: Case Studies and Performance Improvement Initiative abstracts are not eligible for awards.
Electronic Submission & Acceptance
The Call for Abstracts portal is closed.
The submission site works optimally with Microsoft Internet Explorer 7, Safari version 3.2 or higher, or Mozilla Firefox version 6.0 or higher (some aspects may not work so well with Chrome). The Call for Abstracts screen provides links to this free software. The site is available 24 hours a day. Multiple authors can easily review or work on the abstract from different locations. The site supports graphic images, tables (with special characters/symbols), Greek characters and special symbols.
All abstracts submitted must comply with the guidelines to be considered for acceptance.
Abstract grading is blinded. Abstracts are selected on the basis of scientific merit.
Acceptance notifications will be sent in early June 2018.
Authors will be expected to attend the meeting and present their posters.
Abstracts accepted are embargoed for release until the time of presentation at the Heart Failure Society of America’s Scientific Meeting.
Abstracts accepted for presentation will be published as a supplement to the Journal of Cardiac Failure. Authors whose abstracts are accepted give HFSA permission and authority to submit and publish their abstract, without compensation, in the Journal of Cardiac Failure.
HFSA reserves the right to all video or audio recordings of presentations at the 2018 Annual Scientific Meeting
HFSA policy for abstracts does not prohibit concurrent journal publication. The work covered by the abstract must not have been published as a manuscript or abstract prior to 3/31/2018. Abstract data may not be presented at a national meeting or world congress in the U.S. prior to 7/1/2018.
If the abstract is selected, author is required to present their research at the annual meeting to be published in JCF. If they have a conflict, they can allow a co-author present in their place, but will need to notify us in advance. Notification letters will go out in early June. They will have approximately 1 week to accept or decline their invitation to present. If decline, their abstract will not be published in JCF.
Abstracts selected for oral presentation in an award session or a Rapid-Fire session will receive special notification letters with additional information.
To determine if an author has accepted abstract to be presented: Click on “Notifications” on the home page in ADMIN, then click the title of the Notification that was sent to the author. Click “Manage Expiration” and then you can locate the authors control or name or email to see if they accepted their invitation [you will need to know which abstract, because an author can submit more than one abstract]. Another way to do this is to do an abstract search using “Advanced Search.” Click on the session title under the abstract and then locate the abstract within the session to see if they accepted the invitation.
Abstract Submission Guidelines
If an author’s name appears on more than one abstract, it must be identical on each abstract.
The submitting author is designated as the presenting or primary author – the presenting author is shown in green in Oasis. The senior author must always be listed last.
The Heart Failure Society of America is a forum for presentation of novel research findings. Therefore, work covered by the abstract must not have been published as a manuscript or abstract prior to March 31, 2018.
Abstract data may not be presented at a national meeting or world congress in the United States prior to July 1, 2018.
Data should not be “split” to create several abstracts from one. Splitting will result in reduced scores for related abstracts.
Abstracts containing identical or nearly identical data submitted from the same institution or individual will be disqualified.
Informed consent: any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1996;14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. Any procedures performed must meet with prevailing ethical standards.
Use of Animals: All studies involving the use of animals must conform with the 1991 revision of “Guiding Principles in the Care and Use of Animals” (American Physiological Association).
If submitting for an award competition, please check the appropriate box and provide required information. Abstracts submitted for award competition cannot be submitted as Poster Presentation Only.
The submitting author must verify that all co-authors have read and approved the abstract submission.
A disclosure form identifying commercial relationships for all co-authors must be completed online by the submitting author. When the box has been checked, the submitting author is signing and verifying disclosure on behalf of all co-authors. Disclosure information for accepted abstracts will be made available to the 2018 scientific meeting attendees.
Abstract Submissions by Industry
Abstract submissions from industry are allowed. Submissions must focus on science and research, not on specific products or services. Abstract presentations cannot be sales presentations or endorsements for products or services.
Withdrawal of accepted abstracts must be received in writing (via email) by HFSA no later than June 16, 2018 to avoid publication in the Journal of Cardiac Failure supplement.
YouTube Presentation on Abstract & Poster Preparation
A YouTube Presentation has been prepared with detailed advice on abstract and poster preparation, including expert tips and specific examples. All authors will benefit, particularly those who are relatively new to abstract submission. Watch the presentation (Playing time: 28 min.)
Writing an Abstract
Title: Make the title dynamic and conclusive, rather than descriptive
Structure: A well-written abstract typically has the following identified sections: Introduction, Hypothesis, Methods, Results and Conclusions.
Category: Check submission category carefully to assure proper consideration.
Length: Maximum length is 2800 characters, including tables and graphs.
An abstract must have a short, specific title (no abbreviations) that clearly indicates the nature of the investigation. Make the title dynamic and conclusive, rather than descriptive.
Briefly describe the objectives of the study unless they are contained in the title. If applicable, include a brief statement of methods. State findings in sufficient detail to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
Use generic names wherever possible. Use trade names only when necessary.
Avoid beginning sentences with numerals.
Standard abbreviations may be used without definition. Nonstandard abbreviations should be placed in parentheses after the first use of the word or phrase abbreviated.
No references, credits or grant support should be included in the abstract.
No identifying information about patients participating in a study or trial should be used.
Proofread abstracts carefully to avoid errors before submission. No corrections will be allowed or made once abstract has been submitted.
The size limit for an abstract 2,800 characters, including characters in the following: abstract title, body, authors/institutions, table(s) and image(s).